Mehul Kothari recommends Biocon, Aurobindo Pharma for trading gains
According to the technical analyst from Anand Rathi, Aurobindo Pharma can rally to Rs 490; while Biocon can jump to Rs 295.
 "Mehul Kothari recommends Biocon, Aurobindo Pharma for trading gains")
premium
BUY
Aurobindo Pharma
Buy Near: Rs 445
Target: Rs 490
Stop Loss: Rs 430
Aurobindo Pharma has found support at the placement of 200 bars moving average and that too on a monthly scale. This means 200 months average and that can be a huge support. Thus, we advise traders to buy the stock on dips near Rs 445 with a strict stop of Rs 430.
Also Read
BUY
Biocon
Buy Near: Rs 270
Target: Rs 295
Stop Loss: Rs 257
We are witnessing a double bottom formation near Rs 257. In addition there is a bullish hammer kind of formation on the daily scale. Thus, we advise traders to buy the stock on dips near Rs 270 with a strict stop of Rs 257.
(Mehul Kothari - AVP – Technical Research, Anand Rathi Shares & Stock Brokers. Views are personal).
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%